Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial
Paul E. Goss(Harvard University), Lois E. Shepherd(Ontario Institute for Cancer Research), Hannah M. Linden(University of Washington), Angela M. Cheung(Westat (United States)), Sundeep Khosla(WinnMed), Haji Chalchal, Catherine Elliott, Kendrith M. Rowland(Columbus Community Clinical Oncology Program), Kathleen I. Pritchard, Vered Stearns(Johns Hopkins University), Judite Scher(University of Toronto), James N. Ingle(Mayo Clinic), Dawn L. Hershman(Columbia University), J. W. Chapman(Canadian Cancer Society), Tanja Badovinac-Črnjević(Massachusetts General Hospital), Jessica St. Louis(Massachusetts General Hospital), Hyman B. Muss(University of North Carolina at Chapel Hill)
Cited by 53
Related Papers
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
Functional Disability 5 Years after Acute Respiratory Distress Syndrome
|New England Journal of Medicine|2011|2.8k
Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer
|New England Journal of Medicine|2003|2.1k